oxymorphone
oxymorphone structure
|
Common Name | oxymorphone | ||
|---|---|---|---|---|
| CAS Number | 76-41-5 | Molecular Weight | 301.33700 | |
| Density | 1.503 g/cm3 | Boiling Point | 518.627ºC at 760 mmHg | |
| Molecular Formula | C17H19NO4 | Melting Point | 248-249ºC (dec) | |
| MSDS | N/A | Flash Point | 267.456ºC | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
|
Oxymorphone active uptake at the blood-brain barrier and population modeling of its pharmacokinetic-pharmacodynamic relationship.
J. Pharm. Sci. 102(9) , 3320-31, (2013) The aim of this study was to characterize the blood-brain barrier (BBB) transport and pharmacokinetics-pharmacodynamics (PKPD) relationship of oxymorphone and to further elucidate its possible contribution to oxycodone analgesia. The BBB transport of oxymorph... |
|
|
Feasibility study of rapid opioid rotation and titration.
Pain Physician 14(1) , 71-82, (2011) Opioid guidelines recommend opioid rotation and switching for patients who do not achieve adequate pain relief or who experience intolerable adverse events (AEs) with their current opioid. However, specific recommendations and protocols for opioid rotation ar... |
|
|
Hydrophilic interaction LC-MS/MS analysis of opioids in urine: significance of glucuronide metabolites.
Bioanalysis 3(23) , 2603-12, (2011) In clinical laboratories, a large proportion of the toxicology workload is drug confirmations. Our GC-MS method for opioid confirmation detects total codeine, morphine, hydrocodone, hydromorphone, oxycodone and oxymorphone. The objective of this study was to ... |
|
|
The meaning of global outcome measures in pain clinical trials: more than just change in pain intensity.
Clin. J. Pain 29(4) , 289-95, (2013) To understand the factors that contribute to patient and physician global outcome ratings and the extent to which receiving different doses of opioids or placebo might influence the importance of these factors better.A secondary analysis was performed using d... |
|
|
Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients.
J. Anal. Toxicol. 36(4) , 232-8, (2012) The object of this study was to evaluate the metabolism of oxycodone to oxymorphone in a pain patient population using a quantitative liquid chromatography-tandem mass spectrometry analysis of 32,656 urine specimens obtained from pain patients between March 2... |
|
|
Pharmacokinetics of oxymorphone in titi monkeys (Callicebus spp.) and rhesus macaques (Macaca mulatta).
J. Am. Assoc. Lab. Anim. Sci. 50(2) , 212-20, (2011) Oxymorphone is a pure μ-opioid receptor agonist that is commonly used in nonhuman primate medicine and surgery to minimize pain ranging in intensity from moderate to severe. We compared pharmacokinetic profiles and physiologic and behavioral responses to oxym... |
|
|
Pharmacokinetics of oxymorphone in cats.
J. Vet. Pharmacol. Ther. 34(6) , 594-8, (2011) This study reports the pharmacokinetics of oxymorphone in spayed female cats after intravenous administration. Six healthy adult domestic shorthair spayed female cats were used. Oxymorphone (0.1 mg/kg) was administered intravenously as a bolus. Blood samples ... |
|
|
Quantitation of opioids in whole blood by electron impact-gas chromatography-mass spectrometry.
J. Anal. Toxicol. 35(2) , 99-107, (2011) Opioids are frequently encountered in Forensic Toxicology casework. A PubMed literature search was conducted to find a method using electron impact-gas chromatography-mass spectrometry to examine whole blood specimens. A previously published method was identi... |
|
|
The implications of tamper-resistant formulations for opioid rotation.
Postgrad. Med. 124(5) , 101-9, (2012) Because rates of both opioid prescribing and opioid abuse have increased, drug companies have responded by considering strategies to make opioid formulations less attractive for abuse without compromising safety or efficacy for patients with legitimate pain m... |
|
|
Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.
Postgrad. Med. 124(2) , 114-22, (2012) Opioids and antidepressants are frequently prescribed for chronic low back pain (cLBP). This post hoc analysis was conducted to assess the tolerability of oxymorphone extended release (ER) for cLBP in patients taking selective serotonin reuptake inhibitors (S... |